Life Sciences Valuations in Tight Capital Markets: When Uncertainty Creates Value
In today’s constrained capital markets, uncertainty has become a primary driver of value in the global life sciences sector. Biotechnology, pharmaceutical, and medical device companies, particularly those operating in innovation hubs such as the United States, Europe, and Asia-Pacific, are increasingly valued on future milestones rather than historical performance. Shifting capital dynamics are reshaping business…